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Mesenchymal stromal cells (MSCs) are capable of differentiating into bone-forming osteoblasts. A recent
Nature Medicine study (Medici et al., 2010) shows that the mislocalized bone in the human disease fibrodis-
plasia ossificans progressiva (FOP) originates from vascular endothelium that gives rise to MSCs.Ectopic bone formation in soft tissues is
a common occurrence following trauma,
internal muscular bleeding, osteoarthritis
(OA), inflammation, and also in specific
genetic disorders. One such condition
is fibrodisplasia ossificans progressiva
(FOP), in which cartilage and bone form
pathologically within soft tissues rather
than only within the skeleton. Olsen
and colleagues studied the source of
ectopic bone in individuals inflicted
with FOP (Medici et al., 2010). Mesen-
chymal stromal cells (MSCs) are multipo-
tent cells with bone-, fat-, and cartilage-
forming potential that are widespread
in calcified and soft tissues and have
been presumed to be the source of
mislocalized bone. In FOP, heterotopic
ossification is thought to occur through
mesenchymal condensation, followed
by chondrogeneis, and finally endochon-
dral ossification. Olsen and colleagues
show that vascular endothelial cells that
undergo endothelial-to-mesenchymal
transition (EndMT) are the source of cells
that generate cartilage and bone lesions
(Medici et al., 2010). This phenomenon
of transdifferentiation of endothelium into
bone, as demonstrated in the FOPmodel,
shows that the human disease recapitu-
lates hallmarks of embryonic plasticity.
The ability of FOP-derived endothelial
cells to undergo EndMT is related to
a mutation in the receptor ALK2, which
causes its constitutive activation. This
observation leaves open the possibility
that the unmutated form of ALK2 might
not mediate EndMT. However, the
authors also demonstrate that activation
of endothelial cells with ALK2 ligands,
such as transforming growth factor
(TGF)-b superfamily cytokines (Figure 1),
results in the transition of endothelium
into mesenchyme. Therefore, EndMT
may be a physiological occurrence, and10 Cell Stem Cell 8, January 7, 2011 ª2011 Enot necessarily restricted to a diseased
state.
The Olson et al. study makes a strong
case that EndMT provides a mechanism
for heterotopic bone formation, based,
in part, on their analysis of diseased tis-
sues. Both humans with FOP and mice
with mutated ALK2 develop heterotopic
bone, the phenotype of which includes
expression of relevant cartilage and
bone markers, as well as the endothelial
markers TIE2 and vWF. These observa-
tions are substantiated through the
use of reporter mice that express an
enhanced green fluorescence protein
(EGFP) transgene under the control of
the endothelial-specific Tie2 promoter.
Analysis of EGFP expression in sections
of ligand-induced heterotopic cartilage
and bone revealed that many green endo-
thelial-derived cells are also Sox9 (carti-
lage) and osteocalcin (bone) positive
(Medici et al., 2010). The hybrid endothe-
lial/mesenchymal phenotype observed
in vivo suggests that mutant ALK2 medi-
ates the transition from endothelium to
cartilage and bone, and results from
subsequent culture experiments support
this hypothesis. Specifically, expression
of the mutant ALK2 in human cultured
endothelial cells (HUCEC) and in human
cutaneous microvascular endothelial
cells (HCMEC) resulted in the acquisition
of fibroblast morphology, associated
with the expression of classical markers
of epithelial-to-mesenchymal transition
(EMT), including Snail and Slug. The tran-
sition of endothelium into mesenchyme is
also supported by the appearance of the
fibroblast marker FSP-1 in early lesions
of the mutant mice induced with the
ALK2 ligand, bone morphogenic protein
(BMP)-4. In both in vitro experiments
and an in vivo immunocompromized
mouse model, the mutant ALK2 express-lsevier Inc.ing endothelial cells gave rise to osteo-
genic, adipogenic, and chondrogenic
mesodermal lineages, consistent with
the proposal that the endothelial cells de-
differentiated into MSCs. This pathway,
involving the acquisition of MSC pheno-
type and function by endothelium, is not
dependent on the presence of the consti-
tutively active, mutant ALK2. Indeed,
endothelial cells exposed to the ALK2
ligands TGF-b2 and BMP4 also differenti-
ated, both in vitro and in vivo, into the
aforementioned three mesodermal line-
ages. Finally, because the knockdown of
this receptor prevented the transition,
the study provides evidence that EndMT
in this system is dependent on signals
downstream of ALK2.
The combination of in vivo observa-
tions, in vitro findings, and the analysis
of the molecular mechanism of EndMT
(Medici et al., 2010) constitute a solid
study that demonstrates an alternate
pathway of chondrogenesis and osteo-
genesis. One caveat to the findings pre-
sented by Olsen and colleagues that will
require further investigation relates to the
current dependence on the expression
of specific cell markers. Surface pheno-
type determination may not always iden-
tify cell lineages faithfully. Further analysis
that establishes specific endothelial func-
tion is required in order to complement
the existing assessment of functional
mesenchymal traits, namely, multilineage
differentiation potential. Future studies
should also explore the possibility that
other cases of ectopic ossification might
be due to EndMT. In osteoarthritis (OA),
as one example, ectopoic ossification
causes severe pain and disability. The
mechanism of OA is not well understood,
and elucidation of the possible contribu-
tion of themicrovasculature is now neces-
sary. Futhermore, EndMT may not be
Figure 1. A Putative Cycle of Cell-Fate Transitions
Vascular endothelium activated by appropriate ALK2 ligands, such as TGF-b2, undergoes an endothelial-
mesenchymal transition (EndMT), leading to acquisition of fibroblast morphology and markers, and multi-
potency that defines mesenchymal stromal cells (MSCs). Multipotency is demonstrated by the ability of
the cells produced by EndMT to differentiate, upon specific induction, into osteoblasts, adipocytes,
and chondrocytes. The reported potential of MSCs to differentiate into endothelial cells completes the
putative cycle. The question mark indicates that this portion of the cycle has not been demonstrated in
the present study.
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bone remodeling and fracture repair may
entail similar processes in which the
vasculature serves as the source of oste-
ogenic cells. In addition, it is tempting to
speculate that EndMT may represent
a physiological mechanism for the gener-
ation of MSCs. Perivascular cells, specif-
ically pericytes (Crisan et al., 2008), have
been suggested to be the in vivo counter-
parts of cultured MSCs. The present
study provides evidence that the endo-
thelium itself serves as an alternative
source.
The observation of EndMT in adult
tissues, albeit diseased, reawakens the
debate as to the plasticity of cell behavior
in the adult. Studies published almost
10 years ago proposed that adult hemato-
poietic stem cells, adult MSCs, and
a variety of tissue-specific progenitors
can undergo transdifferentiation. For
example, Sharkis and colleagues pub-
lished that bone-marrow-derived cells
could produce mature cells of epithelial
organs, such as the liver and lung (Krause
et al., 2001). Other examples of transitions
from one fully differentiated cell type into
mature cells of a different lineage/tissuehave been reported and were suggested
to entail dedifferentiation. The present
report by Olsen et al. can be added to
the list of studies supporting the notion
of cellular plasticity in adult mammalian
tissues. Notably, this report is not iso-
lated. Several other recent studies also
support the possibility that cellular plas-
ticity is neither restricted to the embryo
nor to diseased adult tissues. Studies of
mouse and human spermatogonia high-
light the fact that these cells are easily
reprogrammable under mild conditions
(Conrad et al., 2008), which do not require
the use of harsh genetic manipulations.
Even more striking is the finding that the
dedifferentiation of maturing germ cells
back into spermatogonial stem cells
occurs under stress (Nakagawa et al.,
2007), and even spontaneously and
frequently (Klein et al., 2010), supporting
themodel that dedifferentiation is a physi-
ological phenomenon. An example of
mammalian dedifferentiation and trans-
differentiation has also been recently
observed in the pancreas (Thorel et al.,
2010).
A fraction of the MSC population
constitutes multipotent cells that giveCell Stem Celrise to a variety of cell types, including
endothelium (Conrad et al., 2009). Thus,
a complete cycle may exist in which
EndMT leads to the formation of MSCs,
which, in turn, differentiate back into
endothelium through a mesenchymal-to-
endothelial transition (MEndT) (Figure 1).
This reversibility in cell-fate determination
has been used to propose the model of
a ‘‘stem state’’ (Zipori, 2004), in which
stemness is considered a transient state
in a cell’s life cycle. In other words, cells
may differentiate, but this change does
not determine their status permanently.
Upon demand for tissue repair, cells
downstream in the differentiation cas-
cade may ‘‘turn back’’ and re-exhibit
stemness by regaining additional lineage
potentials that had previously been lost.
The stem state notion predicts that dedif-
ferentiation is possible in mammalian
tissues (Zipori, 2009), and this proposal
is supported by the current findings
that supposedly unipotent adult endothe-
lium can, when prompted, re-exhibit
multipotency.REFERENCES
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